180 Life Sciences Corp. Enters into a License Agreement with University of Oxford for Regenerative Molecule HMGB1 for Liver Diseases
PALO ALTO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) — 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has entered into a new, exclusive global licensing agreement with The University of Oxford (“Oxford”) for the development and commercialization of HMGB1, a regenerative molecule for promoting liver repair and regeneration. Under the terms of the transaction, the Company will pay Oxford a small one-time upfront licensing fee, which will have an insignificant impact on the 2022 expenditure rate; any further payments are contingent upon the achievement of certain clinical, regulatory and sales milestones.
